Lung cancer drug Gilotrif (afatinib) looks set to make inroads in markets outside the USA after promising clinical trial data was published, analysts believe.
But Gilotrif, German family-owned drug major Boehringer Ingelheim’s tyrosine kinase inhibitor (TKI), is unlikely to seriously compete with market leader Tarceva (erlotinib), according to experts from research and consulting firm GlobalData.
LUX-Lung 7 trials showed Gilotrif reduced the risk of adenocarcinoma progression for patients with epidermal growth factor receptor (EGFR) mutations by 27% compared with one of its closest rivals, AstraZeneca’s (LSE: AZN) Iressa (gefitinib).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze